Drug Approval | August 26, 2021
Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin
The company to receive upfront and milestone payments, in addition to royalties
The company to receive upfront and milestone payments, in addition to royalties
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Subscribe To Our Newsletter & Stay Updated
